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Introduction: Advancement of novel anticancer drugs into clinical use is frequently halted
by their lack of solubility, reduced stability under physiological conditions, and non-specific
uptake by normal tissues, causing systemic toxicity. Their progress to use in the clinic could
be accelerated by the development of new formulations employing suitable and complemen-
tary drug delivery vehicles.
Methods: A robust method for apoferritin (AFt)-encapsulation of antitumour benzothiazoles
has been developed for enhanced activity against and drug delivery to benzothiazole-
sensitive cancers.
Results: More than 70 molecules of benzothiazole 5F 203 were encapsulated per AFt cage.
Post-encapsulation, the size and integrity of the protein cages were retained as evidenced by
dynamic light scattering. ToF-SIMS depth profiling using an argon cluster beam confirmed 5F
203 exclusively within the AFt cavity. Improved encapsulation of benzothiazole lysyl-amide
prodrugs was achieved (~130 molecules of Phortress per AFt cage). Transferrin receptor 1,
TfR1, was detected in lysates prepared from most cancer cell lines studied, contributing to
enhanced anticancer potency of the AFt-encapsulated benzothiazoles (5F 203, Phortress, GW
610, GW 608-Lys). Nanomolar activity was demonstrated by AFt-formulations in breast,
ovarian, renal and gastric carcinoma cell lines, whereas GI50 >50 µM was observed in non-
tumourigenic MRC-5 fibroblasts. Intracellular 5F 203, a potent aryl hydrocarbon receptor
(AhR) ligand, and inducible expression of cytochrome P450 (CYP) 1A1 were detected follow-
ing exposure of sensitive cells to AFt-5F 203, confirming that the activity of benzothiazoles
was not compromised following encapsulation.
Conclusion: Our results show enhanced potency and selectivity of AFt-encapsulated 5F 203
against carcinomas derived from breast, ovarian, renal, colorectal as well as gastric cancer
models, and offer realistic prospects for potential refinement of tumour-targeting and treat-
ment, and merit further in vivo investigations.
Keywords: benzothiazole, apoferritin, transferrin receptor, anticancer activity, drug delivery
Introduction
Development of drug delivery vehicles is of great importance for advancement of
novel drugs into the clinic, and could be used to address their limited solubility,
stability in physiologically relevant solvents, provide targeted delivery of the drug,
hence limiting systemic toxicities.1 These disadvantages are often only apparent at
later phases in drug development. Nanomedicine has already enabled significant
progress in the development of advanced therapeutic agents and further investigations
are ongoing to achieve successful translation into the clinic.2–4 Several drug delivery
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nano-vehicles have been identified, including ones derived
from lipids,5 synthetic polymers6,7 and proteins.8 Of parti-
cular interest are protein capsules as they are biocompatible,
biodegradable and species-specific, hence they are not
expected to accumulate in the body or induce an immune
response if species matched.9 Of additional benefit is the
possibility to genetically modify the protein surface for
attachment of targeting molecules.10 Proteins from the fer-
ritin family, such as apoferritin (AFt) and Dps have
emerged as promising candidates for drug delivery and
have been successfully used to encapsulate small molecules
and imaging agents.11–13 Encapsulation of anticancer ther-
apeutic agents into AFt has attracted considerable attention
due to internalisation of AFt-encapsulated cargo via trans-
ferrin receptor 1 (TfR1)-mediated endocytosis14,15 and cel-
lular recognition of modified AFt by receptors, such as
EGFR, which are overexpressed in specific cancers.16
Despite promising applications, AFt encapsulation of
drugs remains challenging and the procedure requires
optimization.
The experimental antitumour agents 2-(4-amino-
3-methylphenyl)-5-fluorobenzothiazole (5F 203, Figure
1a) and 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole
(GW610; Supplementary Information Scheme S1) elicit
exquisitely potent and selective anticancer activity in cer-
tain cancer models via a mechanism distinct from current
clinical anticancer therapies.17,18 The compounds are
potent aryl hydrocarbon receptor (AhR) ligands, and
induce their own cytochrome P450 (CYP) 1A1 and 2W1-
catalyzed metabolism to generate electrophilic species
which then form DNA adducts leading to lethal DNA
double-strand breaks; this occurs exclusively in sensitive
phenotypes.19 However, systemic exposure and adverse
toxicity in potentially susceptible healthy tissues (e.g.
lung, liver)20 and the poor water-solubility of 5F 203
limit its advance into the clinic.
Here we develop a new formulation of 5F 203 addressing
its toxicity and solubility. The agent has been encapsulated
within horse spleen AFt protein cages. AFt-encapsulation
protocols have been systematically investigated to optimize
encapsulation efficiency; complementary characterization
techniques have been employed to study AFt integrity and
confirm 5F 203 encapsulation. Direct determination of
encapsulation of 5F-203 inside the AFt cage was achieved
by TOF-SIMs. The antitumour activity of the AFt-
encapsulated agents was interrogated in breast, ovarian,
renal, colorectal, lung and gastric cancers; concurrently, stu-
dies were undertaken to verify that the cellular mechanism of
action of 5F 203 was not compromised following its encap-
sulation in AFt nanocages.
Materials and Methods
Encapsulation Methods
Encapsulation of 5F 203 was performed using both the
nanoreactor and reassembly routes (Figure S1). In the
nanoreactor route, molecules are encapsulated by passive
diffusion through 3 and 4 Angstrom channels at the protein
junctions in the AFt shell. In the reassembly route, the
ability of the AFt cage to disassemble into its subunits and
reassemble is used to entrap the cargo. Two triggers were
used for reassembly: pH-dependent and urea-induced reas-
sembly. Horse spleen ferritin (Sigma Aldrich) was used to
prepare AFt and was used for encapsulation.
The optimized nanoreactor method was used for sub-
sequent encapsulation of Phortress, GW610 and GW 608-
Lys. The chemical structure of all test agents is shown in
Scheme S1.
Characterisation methods: UV-vis spectroscopy: The
benzothiazole concentrations were determined by mea-
surement of absorbance at 360, 334, 325 and 336 nm for
5F 203, GW 610, Phortress and GW 608-Lys, respec-
tively, on a Varian Cary50 UV-Vis spectrometer, using
a calibration curve (R2 > 0.999) obtained from samples
of known benzothiazole concentration. Transmission elec-
tron microscopy: For transmission electron microscopy
(TEM), the samples were deposited onto graphene oxide-
coated copper grid and images were acquired on a JEM-
2100F, JOEL operated at 200 kV. Dynamic Light
Scattering (DLS): DLS analyses were carried out at 25ºC
using a Zetasizer Nano spectrometer (Malvern
Instruments Ltd) equipped with a 633 nm laser at a fixed
angle of 173º. ToF-SIMs: Time of Flight Secondary Ion
Mass Spectrometry (ToF SIMS) analysis was carried out
on a ToF-SIMS IV instrument (ION-TOF GmbH,
Munster, Germany) equipped with a bismuth liquid
metal ion gun and a single-stage reflectron analyser.
Bradford assay: The AFt concentration was determined
by Bradford assay. Briefly, 10 µL of sample was diluted
in 90 µL of d.H2O in a 96-well microliter plate and 140
µL of Bradford reagent was added. After 5-min incuba-
tion, the plate was read at 595 nm using a Perkin Elmer
plate reader. A calibration curve was constructed, using
bovine serum albumin (BSA) from 0.1 to 1.0 mg mL−1
and used to convert absorbance readings to protein
concentrations.
Breen et al Dovepress
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In vitro Cell Culture Studies
All cell lines were purchased from the American Type
Culture Collection (ATCC) and cultured in RPMI 1640 med-
ium supplemented with 10% v/v foetal bovine serum (FBS)
at 37°C in an atmosphere of 5% CO2. Cells were passaged
twice weekly to maintain continuous logarithmic growth. In
this work, we have used the following human-derived cell
lines: non-tumourigenic foetal fibroblast MRC-5; breast can-
cer cell lines MCF-7, MDA-MB-468, renal cancer cell TK-
10, ovarian cancer cell IGROV-1, colorectal cancer cells
HCT 116, HCC 2998 and KM12; gastric cancer cells
MKN-45, NCI-N87, KATO-III, BGC-823 and SGC-7901.
For MTT assays, cells were seeded at a density of
5×103 cells per well into 96-well plates and allowed 24
hrs to adhere. Serial dilutions were prepared in medium
and added to cells (n = 4 per concentration). Viable cells at
the time of test agent addition (T0), and following 72 hrs
of drug exposure were determined by cell-mediated
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction. MTT was added to each well
(final concentration 400 μg mL−1) and incubated for 3
hrs at 37°C. Well supernatants were aspirated and forma-
zan solubilized with 150 μL DMSO. Absorbance was read
at 550 nm using Perkin Elmer Envision plate reader. The
GI50 values were determined by interpolation.
For clonogenic assays, 250 cells per well were seeded
into 6-well plates and allowed 24 hrs to attach. Test
compounds were added at GI50 concentrations. After 24
hrs exposure, the medium was aspirated and cells washed
with PBS (2 × 1 mL) before incubation in medium (2 mL)
for 7–9 days. Experiments were terminated when colonies
≥ 50 cells were observed in control wells. Colonies were
washed (PBS, 2× 1 mL), fixed (methanol, 15 mins),
stained (0.5% methylene blue, 15 mins) and counted.
Confocal Microscopy
Following required treatments, cells were lysed and pro-
teins separated by SDS-PAGE then electroblotted onto
PVDF membranes, Membranes were blocked in Tris-buf-
fered saline (TBS) containing 5% milk and 0.1% Tween-
20 (1 hr), then incubated with 1o Abs (CYP 1A1, TfR1;
Cell Signaling; O/N, 4oC). Membrane incubation with 2o
Abs preceeded ECL detection. Images were examined on a
C-DiGit blot scanner (LI-Cor-Biosciences). Cells were
seeded at a density of 2×105 in wells with coverslips and
allowed 24 hrs to attach. Following 24 hrs exposure to the
test compound, live images of the cells were taken using
a Zeiss LSM 510 fluorescence microscope equipped with
a UV laser.
Statistical Analysis
All experiments were repeated at least three times and
results are reported as mean ± standard deviation (SD).
Statistical significance was assessed using ANOVA.
Results and Discussion
Development and Optimization of AFt
Encapsulation Method
Encapsulation of 5F 203 was performed using both nanor-
eactor and reassembly routes (Figure 1), following the
Figure 1 (A, left) Chemical structure of test agents 5F 203 and Phortress and
(right) a cartoon and a representative dark field TEM image of Apoferritin-
encapsulated 5F 203. (B) TOF SIMs Mass spectra of AFt-5F 203. (C) A summary
of intensity change with increasing sputter time.
Dovepress Breen et al
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modified method developed for encapsulation of
nanocrystals.21,22 Initially, a ratio of five molecules of 5F
203 per AFt cage (24 protein subunits per cage, horse
spleen AFt) were mixed together under dialysis (see
Experimental section), however significant amounts of
precipitate formed. The precipitate was removed and the
supernatant was used to assess the concentrations of 5F
203 and AFt by UV-vis spectroscopy and Bradford assays,
respectively. For both the nanoreactor and reassembly
routes, only ~0.5–1.5% 5F 203 and <1% AFt was
detected.
In the nanoreactor route, the number of 5F 203 molecules
was increased to 100 per AFt cage, improving the encapsula-
tion efficiency to 47%; however, the loss of the protein
during encapsulation was still significant. The choice of
buffer is of great importance for AFt stability and solubility.
Hence, sodium acetate buffer (pH 5.5) was replaced by
TRIS-buffer (pH 7.4) which had previously been reported
for encapsulation of doxorubicin [10], but this failed to
decrease protein precipitation. The use of 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer
and a reduced concentration of AFt (halved to ~1.5 mg
mL−1) enabled encapsulation without significant loss of pro-
tein, with up to 72% of AFt remaining in solution. Hence,
HEPES buffer was used to further increase the number of test
agent molecules per AFt cage. Since the aqueous solubility of
benzothiazoles is very low, 5F 203 was added in aliquots
(equivalent of 100 molecules per AFt cage was added at 30
mins intervals). Using this method, we achieved encapsula-
tion of 71 molecules per AFt cage. Dynamic light scattering
(DLS) studies of the resulting solution revealed an average
size of 13.1 ± 1.6 nm, as expected for single AFt cages,
confirming that the size and the integrity of the AFt had not
been affected by encapsulation of 5F 203. Transmission
electron microscopy (TEM) studies confirmed that integrity
of the AFt capsule is not affected by the encapsulation. We
observed the AFt capsules with an average diameter of 11.6 ±
1.9 nm (Figure 1A).
Examining Encapsulation Efficiency of the
Agent
In order to investigate whether the encapsulation efficiency
could be improved using the reassembly route, two methods
were trialed: pH-induced and urea-induced reassembly. For
pH-induced reassembly, 5F 203 was added to AFt subunits
(disassembly at pH = 2) and the pH was raised to pH 4.0
(using 1M, NaOH) and then to 7.4 (by addition of 1M, tris
buffer), to gradually reform the AFt cages. The AFt
remained in solution, but significant loss of test agent was
observed (only 1.3% of test agent encapsulated). To address
obstacles posed by agent solubility, we used a glycine/
HEPES buffer and reduced the concentration of AFt
(1.5 mg mL−1). The reassembly of AFt capsules was
initiated by direct addition of base; this was necessary to
limit the time that the solution was kept in the pH 4.5–6.5
range, which is close to the isoelectric point of the AFt
subunits and could lead to precipitation.12 This method
resulted in >55% of AFt remaining in solution and encap-
sulation of 25 molecules of 5F 203 per AFt cage. However,
DLS studies indicated that the reassembly of the AFt cap-
sule under these conditions was altered leading to the for-
mation of larger protein cages (average diameter 20.9 ±
2.8 nm). Following filtration, only a small fraction of the
samples demonstrated the expected diameter of 12.7 ± 1.8
nm. These results could be associated with the formation of
nanocages larger than the expected 24-mer, or possible
damage to AFt leading to the formation of holes in the
AFt surface.23 It was hypothesised that disassembly of
AFt using the urea method may provide more efficient
protein reassembly;24 However, the results of encapsulation
were similar to those obtained using the pH method. Since
the reassembly routes failed to increase the encapsulation
efficiency, the nanoreactor method with gradual addition of
the test agent as multiple aliquotes was adopted for all
subsequent studies. Encapsulation using the nanoreactor
route was performed at pH 5.5. We anticipate no significant
leakage of the encapsulated agent during storage (pH 7 and
T = 4°C) as AFt pore size is reduced under these conditions.
To confirm that 5F 203 was encapsulated within the AFt
cavity and not bound to the surface, time of flight secondary
ion mass spectrometry (ToF-SIMS) was performed
(Figure 1B and C). We observed a series of distinctive
peaks corresponding to AFt at 56–58 m/z range and to 5F
203 at 255–295 m/z range. With increasing sputter time, the
intensity of the peaks at 56–58 m/z is reduced and accom-
panied by increased signal at the 5F 203 range. The peaks
of the drug are not visible in the AFt, until the protein shell
is removed. We note that the signals corresponding to
common contaminants such as Na+, K+, and PDMS did
not reduce with increasing sputter time. Hence, depth pro-
filing using an Argon cluster beam to remove a layer of the
sample was applied and revealed 5F 203 peaks exclusively
below the AFt surface, within the cavity. These ToF-SIMS
results confirm that the drug is encapsulated inside the AFt
Breen et al Dovepress
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cavity and provide the first direct examination of the mor-
phology of the protein encapsulated structures.
In vitro Assessment of Anticancer
Activity
We recently reported that conjugation to a lysine moiety
significantly enhances the encapsulation of benzothia-
zole GW 610 in AFt, resulting in a more potent
formulation.25 Moreover, the lysylamide prodrug of 5F
203 (Phortress) has advanced to clinical evaluation
because of its selective potent antitumour activity
in vitro and in vivo against breast and ovarian cancer
models, unique mode of action and favourable pharma-
cokinetic properties.20,26 Therefore, Phortress, was
encapsulated within AFt. Promising encapsulation
results were achieved with 130 molecules of Phortress
per AFt cage, with a corresponding encapsulation effi-
ciency (EE) of 8% and drug loading of 10%. Phortress
encapsulation efficiency was slightly higher compared to
5F 203, likely a consequence of the difference in polar-
ity and lipophilicity of the test agents (Supplementary
Information SI1, Scheme S1 and Figure S2).
The rate at which test agents are released from
a delivery capsule could significantly impact its therapeutic
properties. Hence, release rates were studied at physiologi-
cally relevant pH values of 7.4 and 6.5. It has been reported
that a lower pH of ~6.5 is normally associated with tumour
microenvironments.27 Figure 2 shows that the release of 5F
203 occurs steadily over 24 hrs with 100% release observed
<24 hrs at both pH 6.5 and 7.4 at 37°C. Phortress was
readily released from the AFt core with 100% release
observed within 9 hrs. This observation is in contrast to
the reported release of doxorubicin from AFt,24 where no
significant release was observed at pH 7.4 after 60 hrs. This
difference may be attributed to the combination of the size
and polarity of the test agents, i.e. doxorubicin is a larger
(544 g mol−1), more polar molecule than 5F 203 (258
g mol−1) and Phortress (386 g mol−1), hence its diffusion
out from the lumen/core through the AFt pores (3–4 Å
diameter) is unlikely at near neutral pH.
To understand the effects of encapsulation on the
in vitro antitumour activity of the benzothiazoles, both
non-encapsulated (naked) and encapsulated forms of 5F
203 and Phortress were tested against a range of cell lines
Figure 2 MTTassay (72 hrs exposure) dose–response curves of (A) 5F 203 and AFt-5F 203 and (B) Phortress and AFt-Phortress in MCF-7, IGROV-1 and MRC-5 cell lines.
Data points are mean ± SD, n = 4 in one representative trial, number of independent trials = 3. Insets: Clonogenic assay displaying survival fractions following 24 exposure
treated at GI50 values in corresponding cell lines. Data points are mean ± SD, taken from 3 independent trials where n=4 per trial.
Dovepress Breen et al
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via MTT assays following 72 hrs exposure of cells to test
agent. The cell lines selected for study included: MCF-7,
MDA-MB-468 breast, TK10 renal, IGROV-1 ovarian,
HCT 116 colorectal (CRC) cancer cell lines and non-
tumourigenic MRC-5 fibroblasts. The results of the MTT
tests are summarised in Table 1 and representative dose–
response curves are illustrated in Figure 2 and SI Figures
S3 and S4. In the majority of sensitive cell lines, the
encapsulated benzothiazole is more potent than the naked
agent. The increase in potency for example in TK10 renal
and IGROV-1 ovarian cell lines, respectively, is ~4× and
>300× for AFt-5F 203, and >60× and 3× for AFt-
Phortress. In the benzothiazole-insensitive cell line HCT-
116 and in non-tumorigenic fibroblasts (MRC-5), both 5F
203 and Phortress were inactive (GI50 values >50 µM). No
growth inhibition was encountered following AFt-
encapsulation of either agent in MRC-5 cells (Table 1)
confirming that cancer cell-selectivity is preserved follow-
ing encapsulations. Surprisingly, HCT 116 CRC cells
(which do not express inducible CYP1A1; SI Figure 3)
did demonstrate sensitivity to AFt-Phortress (Table 1 and
Supplementary Information SI2 and Figures S3 and S4).
Similar to the naked agent, AFt-5F 203 was more active
than AFt-Phortress in all sensitive cell lines tested, exem-
plified by increased potency (with correspondingly
reduced GI50 values) by factors of ~1.5× in IGROV-1,
and 3.5× in TK-10. However, if GI50 values in relation
to AFt concentration are considered, AFt-Phortress is more
potent (than AFt-5F 203) in the sensitive cell lines tested,
increasing potency by a factor ranging from ~3× for MCF-
7 and up to ~22× for TK-10. The in vitro antitumour
activity observed in the MTT assays was corroborated by
clonogenic assays (Figure 2, SI S3 and S4). Clonogenic
survival was inhibited in all sensitive cell lines tested and
AFt-encapsulated benzothiazoles were either equally, or
more potent than free drug. Thus, not only is the enhanced
potency of encapsulated benzothiazoles confirmed, but
importantly, clonal survival of benzothiazole-sensitive
cancer cells is inhibited following brief exposure of cells
to AFt-5F 203 and AFt-Phortress. AFt alone did not cause
growth inhibition or toxicity in either the MTT or clono-
genic assays (up to 1 mg mL−1), confirming the biocom-
patibility of this protein and its potential for drug delivery
applications.
We envisage that the enhanced toxicity of the encapsu-
lated agents is a consequence of cellular recognition of
AFt by the transferrin receptor (TfR1) and receptor-
mediated endocytosis.28 Membrane TfR1 expression is
markedly upregulated in many cancers including colon
and breast.14,16 To examine this hypothesis, we assessed
TfR1 expression in the studied cell lines. The results
confirm TfR1 expression in lysates of most cancer cells,
Table 1 GI50 Values Calculated from MTTAssay (72 Hrs) of Naked and Encapsulated Forms of 5F 203 and Phortress. GI50 Is Mean ±
SD from Three Independent Trials, Where N = 4
Cells Line Test Agent
5F 203 AFt-5F 203 Phortress AFt- Phortress
GI50 ± SD (µM) MCF-7 0.005 ± 0.0006 0.033 ± 0.009 0.085 ± 0.017 0.063 ± 0.030
MDA-468 0.014 ± 0.007 0.008 ± 0.008 0.11 ± 0.013 0.11 ± 0.035
TK-10 0.11 ± 0.09 0.028 ± 0.004 6.3 ± 2.9 0.098 ± 0.008
IGROV-1 12.8 ± 10.2 0.039 ± 0.011 0.17 ± 0.070 0.058 ± 0.022
HCT-116 >50 >0.61 >50 0.14 ± 0.059
MRC-5 >50 >0.61 >50 >2.5
Figure 3 (A) Confocal microscopy images of MCF-7 cells and following 24 hrs
exposure of cells to AFt, 5F 203 alone and AFt-5F-203 prepared via nanoreactor
route. (B) Selective induction of CYP1A1 protein in lysates of sensitive MCF-7 cells
only following exposure to naked and encapsulated agent (24 hrs; 1 µM 5F 203);
lysates prepared from HCT 116 cells express neither inducible nor constitutive
CYP1A1.
Breen et al Dovepress
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revealing an order of TfR1 expression in benzothiazole-
sensitive carcinoma cell lines as follows: KM-12 > MCF-7
> TK-10 > HCC-2998 > IGROV-1 > MDA-MB-468
(Supplementary Information SI2 and Figures S5 and S6).
Insensitive MRC-5 fibroblasts showed undetectable levels
of TfR1 expression, whereas TfR1 expression was evident
in HCT 116 lysates. These results are consistent with
observed differences in GI50 values following benzothia-
zole encapsulation. For example, the highest expression of
TfR1 was seen in KM-12 cells; as reported, enhanced
potency of AFt-encapsulated benzothiazoles GW 610 and
GW608-Lys, by ~50- and >750-fold, respectively, was
seen in this cell line.25 Moderate expression of TfR1 in
TK-10 (and HCC-2998) cells corresponded to ~4-fold and
~64-fold enhanced activity of AFT-encapsulated 5F 203
and Phortress in TK10 cells. No TfR1 expression was
detected in MDA-MB-468 cells, and no difference was
observed in GI50 values of naked or encapsulated
Phortress (0.11 µM).
In the benzothiazole-insensitive HCT 116 cell line,
growth inhibition was observed following exposure of
cells to AFt-Phortress, facilitated (we speculate) by TfR1-
mediated endocytosis of the AFt formulation. However,
direct correlation between TfR1 expression and GI50
values was not observed in MCF7 and IGROV-1 cell
lines. There is strong TfR1 expression in MCF-7 cells;
however, there was no enhanced potency of the encapsu-
lated benzothiazoles; in IGROV-1 cells, there is minimal
TfR1 expression, however dramatically increased potency
following encapsulation of 5F 203 was observed.
Abundant cytosolic AhR expression in MCF-7, IGROV-1
(and MDA-468) cells promotes rapid depletion of 5F 203
from nutrient medium, sequestration and ligand-receptor
binding.29 Un-encapsulated (naked) benzothiazoles rely on
passive diffusion and their hydrophobic nature to cross the
cell membrane and enter cells. Cytosolic AhR expression
in cancer cells correlates with rapid sequestration of anti-
tumour benzothiazoles such as 5F 203. These observations
correlate with CYP1A1 induction and generation of DNA
adducts over the initial 24 hrs exposure of MCF-7 and
IGROV-1 cells to 5F 203, or Phortress.30,31
Cellular Uptake of AFt-Encapsulated
Agents
Confocal microscopy was performed following exposure of
MCF-7 cells to naked and AFt-encapsulated 5F 203
(Figure 3). Additionally, lysates were prepared from MCF-
7 and HCT 116 cells exposed to naked and AFt-
encapsulated 5F 203 and induction of CYP1A1 protein
expression was examined to investigate AhR-signal trans-
duction activation by 5F 203 (a potent AhR ligand).32
Intracellular 5F 203 was clearly observed in MCF-7 cells
exposed to both naked and AFt-encapsulated 5F 203
(Figure 3A). Moreover, clear expression of CYP1A1 pro-
tein exclusively in benzothiazole-sensitive MCF-7 cells
exposed to naked and AFt-encapsulated 5F 203 provided
evidence of AhR signal transduction. AFt alone did not
induce CYP1A1, and no CYP1A1 protein was detected in
lysates of insensitive HCT 116 cells exposed to 5F 203 or
AFt-5F 203 (Figure 3B). As inferred, the surprising activity
observed following exposure of HCT 116 cells to AFt-
Phortress maybe a consequence of its TfR1-mediated cel-
lular internalization. We conclude that CYP1A1-inducibility
by antitumour benzothiazoles is not compromised following
encapsulation in AFt protein nanocages.
Studies in Gastric Cell Lines
Encapsulation of benzothiazoles into the AFt cavity offers
a number of advantages compared to other delivery vehi-
cles, such as enhanced solubility, bioavailability and selec-
tive uptake. Passive tumour-targeting to the tumour
microenvironment can be achieved via EPR, and active
tumour targeting via TfR1-mediated internalization (and
cytosolic AhR-mediated sequestration). Only a subset of
cancers demonstrates sensitivity to antitumour benzothia-
zoles with ≥4 log-fold selectivity between sensitive and
Figure 4 Histograms of GI50 values for all gastric cell lines treated with 5F 203 and
AFt-5F 203; means ± SEM from 3 independent trials; n=4 per trial. (Inset)
Representative dose–response profiles following exposure of gastric cell line
MKN-45 to 5F 203 and AFt-5F 203. MTT assays were performed after 72 hrs
treatments.
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inherently resistant phenotypes.33–36 Sensitive tumour
types can be identified through ex vivo examination of
activity and pharmacodynamic (PD) biomarkers of sensi-
tivity (AhR, DNA adducts).37
An additional important benefit of AFt encapsulation, as
alluded to in ref. [27], is the sensitivity of the protein capsule
to pH, which could offer drug delivery and treatment advan-
tage for gastric cancer. The AFt cage would disassemble in
this highly acidic environment releasing its cargo, in this case
a potent AhR ligand, locally, at the tumour site. AhR is
expressed by gastric cancer cells and plays a role in gastric
carcinogenesis.38,39 Moreover, CYP1A1 mRNA and protein
expression are inducible in gastric cancer, and CYP 2W1
protein, embryonically expressed in gastrointestinal tissues is
highly expressed in gastric cancer.40
Our studies in gastric cancer models further validated
the selective activity in vitro and efficacy in vivo of 5F
203, revealing correlation in this cancer phenotype
between benzothiazole activity and CYP 1A1 induction/
CYP2W1 expression.41 In our preliminary studies, ~10-
fold enhanced potency was observed for AFt-encapsulated
compared to naked 5F-203 in NCI-N87 cancer cells (GI50
values of 0.04 μM and 0.38 μM, respectively, were
obtained); ~7-fold increased activity was seen in MKN-
45 cancer cells following 5F 203 AFt-encapsulation (GI50
values: 5F 203, 0.011 μM; AFt-5F 203, 0.079 μM). In
KATO-III cells, GI50 values of 33.3 μM (5F 203) and
0.26 μM (AFt-5F 203) reflect >100-fold enhanced potency
following AFt-encapsulation (Figure 4A and Table 2).
Further enhancement of the activity of observed following
AFt-encapsulation of benzothiazoles GW 610 and
GW608-Lys (~180 and ~380 molecules/AFt cage,
respectively),25 where up to 100-fold reduction in GI50
values was observed for encapsulated agents in the
MKN-45 gastric cell line (Figure 4B and C and Table 2).
We envisage that potency may be further enhanced in vivo
where agents will be exposed to pH ~2. These results
demonstrate a significant advantage of the AFt delivery
capsule and merit further assessment in vivo.
Conclusions
In conclusion, we have developed and optimized a robust
biocompatible, formulation for antitumour benzothiazoles
that involves encapsulation within AFt protein cages for
selective treatment of benzothiazole-sensitive cancer phe-
notypes. Improved encapsulation has been demonstrated for
lysylamide prodrugs Phortress and GW 608-Lys compared
to parent 5F 203 and GW 610, respectively; enhanced
in vitro antitumour activity of AFt-encapsulated formula-
tions compared to naked 5F 203, Phortress, GW 610 and
GW 608-Lys has been encountered; finally, potency against
carcinomas derived from breast, ovarian, renal, colorectal
as well as gastric cancer models, for which cargo-release at
low pH is pertinent, has been demonstrated. Our results
herald exciting prospects for potential refinement of
tumour-targeting, imaging (e.g. fluorescence of 5F 203
itself or 18F-labelled 5F 203) and treatment, and merit
further in vivo investigations.
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Table 2 Summary of GI50 Values Calculated from MTT Assay (72 Hrs) in Gastric Cell Lines for All Test Agents. GI50 Is Mean ± SD
from Three Independent Trials, Where N = 4
Test Agent GI50 ± SD (µM)
Cell Line
MKN-45 NCI-N87 KATO-III BGC-823 SGC-7901
5F 203 0.079±0.026 0.38 33.3±20.9 >51 14.1±18.5
AFt/5F 203 0.011±0.004 0.029±0.013 0.26±0.2 >0.7 >0.7
GW610 0.43±0.37 0.41±0.34 7.7±1.1 18.6±14.1 35.1±8.6
AFt-GW610 0.036±0.032 0.48±0.34 0.42±0.33 1.4±0.5 >1.8
GW608Lys 22.1±16.8 38.1 41.7±21.4 >50 25.9±22.5
AFt/GW608Lys 0.21±0.13 0.59 >3.5 >3.5 >3.5
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